Clinical Trials

Offering Cutting Edge Treatments

When possible, we offer our patients the option to participate in clinical trials. Clinical trials allow cutting edge treatment options to be tested by the people they were designed to help.

Clinical Trials AdobeStock

Trials Open to Enrollment

If you are interested in any of these open opportunities, we encourage you to call our office or talk with your provider to explore your options.

Protocol AU-011-301: September 2023 -Present:

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects with Primary Indeterminate Lesions or Small Choroidal Melanoma

Sponsor: Aura Biosciences, Inc. identifier: NCT06007690

Status: Open to Enrollment

Protocol AL: November 2023 -present:

A Randomized Clinical Trial Evaluating Intravitreal Faricimab (6.0 mg) Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of Visual Acuity Loss due to Radiation Retinopathy (Protocol AL)

Sponsor: Jaeb Center for Health Research (JCHR) identifier: NCT05844982

Status: Open to Enrollment

UBX1325-04: September 2023-present:

A Phase 2b, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients with Diabetic Macular Edema

Sponsor: UNITY Biotechnology, Inc. identifier: NCT06011798

Status: Open to Enrollment

Trials In Follow-Up

Feel free to contact our office with any questions about these opportunities currently in the follow-up stage.

Protocol ALXN2040-GA-201: November 2022-present:

A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Sponsor: Alexion Pharmaceuticals, Inc. Identifier: NCT05019521

Status: Closed to Enrollment

Protocol OPT-302-1005: April 2021-present:

A Phase 3, Multicenter, Double-masked, Randomized Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)

Sponsor: Opthea identifier: NCT04757636

Status: Closed to Enrollment

Study Protocol ISIS 696844-CS5: March 2021-present:

A Phase 2, Randomized Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-Lrx, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

Sponsor: Ionis Pharmaceuticals, Inc. Identifier: NCT03815825

Status: Closed to Enrollment

Completed Studies

Our team would love to talk more with you about these completed studies and what other opportunities are available.

202 Study Protocol AU-011-202: August 2020 – present:

A Phase 2 trial of AU-011 via suprachoroidal administration with a dose escalation phase (open-label, ascending single and repeat dose) and a randomized, masked dose expansion phase designed to evaluate the safety and efficacy of AU-011 in subjects with primary indeterminate lesions and small choroidal melanoma.

Sponsor: Aura Biosciences, Inc. Identifier: NCT04417530

Status: Closed

Study Protocol KS301P103: July 2021-present:

A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Due to Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion (RVO)

Sponsor: Kodiak Sciences, Inc. Identifier: NCT04592419

Status: Closed

Protocol GR41987: July 2021-present:

A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients with Diabetic Macular Edema

Sponsor: F. Hoffman-La Roche Ltd Identifier: NCT04432831

Status: Closed

Study Protocol UBX1325-02: July 2021-present:

A Phase 2a, Prospective, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients with Diabetic Macular Edema

Sponsor: UNITY Biotechnology, Inc. Identifier: NCT04857996

Status: Closed

Learn More About Clinical Trials

If you are interested in learning more about any of these opportunities or next steps, please contact our office.

Translate »